Dr. Ursula Wiedermann
Chief Scientific Officer
Biopharmaceutical
Imugene
Australia
Biography
Dr. Ursula Wiedermann has been appointed as Chief Scientific Officer of Imugene Ltd., with effect from 5 June 2015. Prof Dr Wiedermann has worked as the Principal Investigator for the preclinical development of HER-Vaxx alongside Professor Christophe Zielinski, and currently serves on the Company’s scientific advisory board. Together they performed the Phase I Clinical trial of HER-Vaxx in metastatic breast cancer patients. Prof Dr Wiedermann is the Professor of Vaccinology at the Medical University of Vienna, one of the oldest and largest medical campuses in Europe. She has a distinguished scientific career with a particular interest in immunology and vaccines, has over 110 publications in peer reviewed scientific journals to her credit and is a frequent speaker at international conferences.
Research Interest
Breast cancer
